Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.2 SEK | 0.00% | +2.47% | +31.75% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.75% | 33.53M | - | ||
+37.78% | 705B | C+ | ||
+32.82% | 583B | B | ||
-3.51% | 364B | C+ | ||
+19.94% | 332B | B- | ||
+5.14% | 291B | C+ | ||
+16.64% | 238B | B+ | ||
-4.13% | 210B | A+ | ||
+10.63% | 209B | B- | ||
+9.32% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- MAGLE Stock
- Ratings Magle Chemoswed Holding AB